Jetrea

Drug Overview

In the field of Ophthalmology, managing conditions that affect the delicate interface between the vitreous humor and the retina is critical for preserving central vision. JETREA represents a specialized pharmacological intervention within the Proteolytic Enzyme drug class. Unlike many ophthalmic treatments that manage chronic symptoms, JETREA is designed as a targeted biochemical solution for structural abnormalities within the eye.

JETREA is a recombinant truncated form of human plasmin. It is specifically engineered to address pathologies involving the vitreous body’s attachment to the macula the part of the eye responsible for sharp, central vision. By acting as a molecular “scissor,” it facilitates the non-surgical separation of these tissues.

• Generic Name: Ocriplasmin
• US Brand Name: JETREA
• Route of Administration: Intravitreal Injection (administered directly into the vitreous cavity by a retinal specialist)
• FDA Approval Status: Approved for the treatment of symptomatic Vitreomacular Adhesion (VMA)
• Manufacturer: Oxurion (formerly ThromboGenics)
  
  Learn about Jetrea, a specialized proteolytic enzyme injection approved for the non-surgical treatment of Symptomatic Vitreomacular Adhesion (VMA).

What Is It and How Does It Work? (Mechanism of Action)

To understand how JETREA functions, one must first understand the anatomy of the posterior segment of the eye. The vitreous is a gel-like substance that fills the eye. As we age, this gel liquefies and naturally pulls away from the retina. However, in some patients, the vitreous remains “stuck” to the macula. This is known as Vitreomacular Adhesion (VMA). When this adhesion exerts physical pulling or “traction” on the macula, it causes distorted or blurred vision, a condition known as Vitreomacular Traction (VMT).

JETREA functions as a Proteolytic Enzyme. At the molecular level, Ocriplasmin possesses enzymatic activity against specific protein components of the vitreoretinal interface. Its mechanism of action involves the targeted breakdown (proteolysis) of:

1. Laminin: A major glycoprotein in the internal limiting membrane (ILM) of the retina.
2. Fibronectin: A protein that acts as a “glue” between the vitreous cortex and the retina.
3. Collagen Type IV: A structural component of the basement membrane.

By dissolving these specific protein scaffolds, JETREA induces a pharmacological posterior vitreous detachment (PVD). Essentially, the enzyme liquefies the protein bonds holding the vitreous to the macula, allowing the vitreous to separate cleanly without the need for invasive “peeling” during surgery. This Targeted Therapy aims to relieve the mechanical stress on the retinal layers, allowing the macula to return to its normal anatomical position and improving visual outcomes.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for JETREA is the treatment of Symptomatic Vitreomacular Adhesion (VMA). This includes cases where the adhesion has progressed to Vitreomacular Traction (VMT), leading to symptoms such as metamorphopsia (distorted vision) or decreased visual acuity. It is particularly indicated for patients who have a small-to-medium-sized adhesion (less than or equal to 1500 microns) and the absence of an epiretinal membrane (ERM).

Other Approved & Off-Label Uses

While JETREA is a highly specialized Proteolytic Enzyme, its use is strictly limited compared to broad-spectrum drugs like VEGF Inhibitors.

• Primary Ophthalmology Indications: * Vitreomacular Traction (VMT): Used to induce the resolution of traction to prevent the formation of macular holes.
  • Macular Hole Closure: Specifically indicated for the closure of full-thickness macular holes (FTMH) with a diameter of less than or equal to 400 microns, provided they are associated with VMA.
  • Pharmacological Vitreolysis: Used as an alternative to “Watchful Waiting” or a pars plana vitrectomy (PPV) surgery in eligible candidates to stabilize the blood-retinal barrier and preserve visual acuity.

Dosage and Administration Protocols

JETREA is administered as a single-use, preservative-free intravitreal injection. The procedure must be performed under strictly controlled aseptic conditions by an ophthalmologist experienced in intraocular injections.

Administration Instructions:

• Preparation: The vial must be thawed at room temperature and diluted with 0.2 mL of sterile, preservative-free 0.9% Sodium Chloride injection prior to use.
• Aseptic Technique: The eye and surrounding area must be cleaned with povidone-iodine, and a sterile speculum should be used.
• Post-Injection: Patients should be monitored for intraocular pressure (IOP) spikes and checked for perfusion of the optic nerve head immediately following the procedure.
• Repeat Dosing: Administration of JETREA in the same eye more than once is NOT recommended.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

The efficacy of JETREA was primarily established through the MIVI-TRUST clinical trials (Multicenter Intravitreal Injection of Ocriplasmin Guideline for Treatment of Uveoretinal Adhesion). These phase III trials provided the data required for global regulatory approvals.

Key Data Points (2020-2026 Perspective):

• VMA Resolution: In pivotal trials, approximately 26.5% of patients treated with JETREA achieved total resolution of VMA by day 28, compared to only 10.1% in the placebo group.
• Macular Hole Closure: For patients with small macular holes (≤250 microns), the closure rate was significantly higher, with nearly 58% achieving closure without surgery.
• Visual Acuity (BCVA): Successful resolution of VMA often correlated with a gain of 2 to 3 lines (10-15 letters) on the ETDRS vision chart over a 6-month follow-up period.
• Anatomical Stabilization: OCT (Optical Coherence Tomography) data showed a significant reduction in Central Retinal Thickness (CRT) in successful responders, indicating a reduction in intra-retinal edema caused by traction.

Recent real-world data (2022-2025) suggests that patient selection is the most critical factor for efficacy. Patients without an epiretinal membrane and those younger than 65 years tended to show higher rates of pharmacological VMA resolution.

Safety Profile and Side Effects

Black Box Warning: There is currently no Black Box Warning for JETREA.

While JETREA is generally well-tolerated, its mechanism as a Proteolytic Enzyme means it can affect various intraocular structures during the enzymatic process.

Common Side Effects (>10%)

• Vitreous Floaters: Often caused by the breakdown of the vitreous gel.
• Photopsia: Sensation of light flashes as the vitreous detaches.
• Conjunctival Hemorrhage: Redness at the injection site.
• Eye Pain: Mild discomfort following the procedure.
• Blurred Vision: Temporary decrease in clarity during the enzymatic process.

Serious Adverse Events

• Retinal Detachment: A rare but severe risk following any intravitreal procedure.
• Endophthalmitis: Severe internal eye infection requiring immediate emergency care.
• Lens Subluxation: Potential weakening of the zonules (fibers holding the lens in place).
• Dyschromatopsia: Temporary changes in color vision (yellowing or “gold” tinting).
• IOP Spikes: Sudden increases in intraocular pressure.

Management Strategies:

Patients are instructed to monitor for “Warning Signs” such as a sudden increase in floaters, a “curtain” over their vision, or severe pain. Sterile administration techniques and post-injection tonometry are mandatory clinical protocols to mitigate these risks.

Research Areas

Direct Clinical Connections

Current research (2024-2026) is investigating the impact of Ocriplasmin on Retinal Pigment Epithelium (RPE) Health. Some studies suggest that while the enzyme is effective at the vitreoretinal interface, long-term monitoring is required to ensure no secondary degradation of the outer retinal layers or RPE occurs. Researchers are also exploring the “synergistic effect” of using JETREA in combination with VEGF Inhibitors for patients who have both VMT and exudative conditions.

Generalization and Novel Delivery

The focus of recent clinical trials has shifted toward Novel Delivery Systems. Specifically, there is interest in whether a Sustained-Release formulation or a lower-dose, micro-dosing strategy could reduce the incidence of transient vision changes like dyschromatopsia. Furthermore, the development of Biosimilars for Ocriplasmin is an active area of interest as original patents reach their transition points in the European and US markets.

Severe Disease & Surgical Integration

In cases of severe vitreoretinal disease, JETREA is being studied as a “Surgical Adjunct.” In complex vitrectomies for diabetic retinopathy, the drug may be used pre-operatively to soften the vitreous and facilitate a safer, more complete removal of tractional membranes, potentially preventing blindness in end-stage cases.

Disclaimer: These studies regarding Ocriplasmin as a surgical adjunct or in combination with gene therapy are currently in the preclinical or early clinical phase and are not yet applicable to standard practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before administering JETREA, a comprehensive ocular workup is mandatory to ensure the patient meets the criteria for successful pharmacological treatment.

• Baseline Diagnostics: Measurement of Best Corrected Visual Acuity (BCVA) and Tonometry to establish baseline Intraocular Pressure (IOP).
• Ocular Imaging: High-definition Optical Coherence Tomography (OCT) is the gold standard for confirming VMA/VMT and measuring the diameter of the adhesion.
• Screening: Patients must be screened for a history of retinal tears, high myopia (which increases detachment risk), or any active ocular infections.

Monitoring and Precautions

• Vigilance: Patients must be seen within 7 days post-injection to check for retinal integrity and IOP stability.
• Lifestyle: Patients should avoid strenuous activity or heavy lifting for 48 hours post-injection.
• Actionable Do’s and Don’ts:
  • DO report any sudden loss of vision or severe pain immediately.
  • DO use any prescribed prophylactic antibiotic drops as directed.
  • DON’T rub the eye for at least 24 hours after the injection.
  • DON’T ignore new “flashes” or a sudden influx of “dark spots” in your vision.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. The use of JETREA involves specific risks that must be discussed with a Retinal Specialist. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.